Table 1.
Demographic data and baseline characteristics of patients.
| CANA/MET (N = 21) | MET (N = 20) | P value | |
|---|---|---|---|
| Age (years) | 26.38 ± 5.89 | 25.55 ± 4.36 | 0.6118 |
| Height (m) | 1.62 ± 0.04 | 1.63 ± 0.05 | 0.4495 |
| Body weight (kg) | 81.23 ± 9.83 | 74.78 ± 8.91 | 0.2365 |
| BMI (kg/m2) | 31.11 ± 3.02 | 29.33 ± 3.19 | 0.1024 |
| FSH (mIU/mL) | 6.58 ± 1.54 | 6.05 ± 1.60 | 0.2800 |
| LH (mIU/mL) | 10.85 (6.36-16.22) | 11.63 (9.69-16.87) | 0.4304 |
| TT (ng/mL) | 0.95 (0.78-1.08) | 0.89 (0.74-1.09) | 0.7616 |
| FAI (%) | 28.62 ± 16.4 | 19.26 ± 9.46 | 0.0738 |
| SHBG (nmol/L) | 13.60 (8.55-20.15) | 18.45 (13.13-21.98) | 0.1626 |
| AND (ng/ml) | 3.57 ± 1.29 | 4.48 ± 1.42 | 0.0715 |
| FBG (mmol/L) | 5.70 (5.27-6.02) | 5.30 (5.16-5.80) | 0.1625 |
| FINS (mU/L) | 21.5 (14.35-24.20) | 16.70 (14.58-24.33) | 0.5919 |
| AUCGlu (mmol/L*min) | 1086 ± 208.7 | 985.3 ± 160.7 | 0.0915 |
| AUCIns (mU/L*min) | 14808 ± 6668 | 13867 ± 7201 | 0.6664 |
| AUCIns/AUCGlu | 13.97 ± 6.83 | 13.90 ± 6.55 | 0.9728 |
| HOMA-IR | 5.70 (3.38-6.08) | 4.25 (3.26-6.44) | 0.6515 |
| TG (mmol/L) | 1.54 (1.09-2.01) | 1.49 (1.07-1.74) | 0.6668 |
| TC (mmol/L) | 4.90 ± 0.93 | 4.74 ± 0.63 | 0.5353 |
| LDL-C (mmol/L) | 3.06 ± 0.97 | 3.01 ± 0.54 | 0.8401 |
| Apo A1 (g/L) | 1.16 ± 0.15 | 1.25 ± 0.20 | 0.1516 |
| Apo B (g/L) | 0.98 ± 0.26 | 0.88 ± 0.18 | 0.2032 |
| Apo B/A1 | 0.85 ± 0.23 | 0.72 ± 0.18 | 0.0732 |
CANA, canagliflozin; MET, metformin; BMI, body mass index; FSH, follicle stimulating hormone; LH, luteinizing hormone; TT, total testosterone; FAI, free androgen index; SHBG, sex hormone-binding globulin; AND, androstenedione; FBG, fasting blood glucose; FINS, fasting insulin; AUCGlu, area under the glucose curve; AUCIns, area under the insulin curve; HOMA-IR, homeostasis model assessment-insulin resistance; TG, triglycerides; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; Apo A1, Apolipoprotein A1; Apo B, Apolipoprotein B.